Proshares Trust (ZBIO) Income from Continuing Operations (2023 - 2025)
Historic Income from Continuing Operations for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$51.5 million.
- Zenas BioPharma's Income from Continuing Operations fell 3339.64% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$193.8 million, marking a year-over-year decrease of 5006.66%. This contributed to the annual value of -$161.3 million for FY2024, which is 33461.64% down from last year.
- Latest data reveals that Zenas BioPharma reported Income from Continuing Operations of -$51.5 million as of Q3 2025, which was down 3339.64% from -$52.2 million recorded in Q2 2025.
- Zenas BioPharma's Income from Continuing Operations' 5-year high stood at $35.6 million during Q3 2023, with a 5-year trough of -$56.5 million in Q4 2024.
- Its 3-year average for Income from Continuing Operations is -$31.9 million, with a median of -$38.0 million in 2024.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 20837.08% in 2024, then tumbled by 2076.62% in 2025.
- Quarter analysis of 3 years shows Zenas BioPharma's Income from Continuing Operations stood at -$24.8 million in 2023, then tumbled by 128.15% to -$56.5 million in 2024, then grew by 8.91% to -$51.5 million in 2025.
- Its last three reported values are -$51.5 million in Q3 2025, -$52.2 million for Q2 2025, and -$33.6 million during Q1 2025.